The Nasdaq is "setting records" because of a handful of companies: Microsoft, AOL, etc., and a few dot.coms. As far as biotech companies, APHT is doing OK. The stock was $7 at their IPO and is around $14 today (better than can be said of many biotechs). They are in trials III in the US now and probably about a year away to hitting the market. No other biotech is doing what they are doing. I still think this one will be a blockbuster. As far as their PR dept., what good has other co's expensive PR done for their share price?? (Nothing). PR MAY only help for the short term - in the long run, the fundamentals are what counts.
Is Aphton really actively in US clinicals? The last announcement said they applied to the FDA to start clinicals. Also, you said that they should probably be hitting the market in a year. What is your source for that information? They do have competition for the market from AVII. If they continue to move at a snails pace, they will miss their opportunity!!! What happened to the asian alliance?
I'm a long time shareholder who is also very disappointed in Aphton. Since they have teamed with MSDW, I feel that the small investor like myself is no longer valued. Try calling the company and judge for yourself!